◀ Back to IFNA2

IFNA2 — S7

Text-mined interactions from Literome

Tabor et al., Dig Liver Dis 2003 (Carcinoma, Hepatocellular...) : The possibility that interferon-alpha might be effective for the prevention or treatment of hepatocellular carcinoma is suggested by its efficacy against the associated hepatitis B and C viruses, by its efficacy in the treatment of some other human tumours, and by evidence that interferon-alpha may inhibit the growth of human hepatocellular carcinoma cell lines and their production of hepatitis B surface antigen
Bingfa et al., Pharmacology 2009 : In vitro, at concentrations from 0.075 to 1.2 nmol/l, rHSA-IFNalpha-2b inhibited the releases of extracellular hepatitis B surface antigen , hepatitis B e antigen and HBV DNA in a dose dependent manner ; rHSA- IFNalpha-2b also increased the levels of STAT1, ISGF3 and OAS1
Yamashita et al., Microbiol Immunol 1988 (Carcinoma, Hepatocellular...) : Recombinant human interferon alpha 2a as well as natural human interferons alpha and beta significantly suppressed the production of hepatitis B surface antigen by PLC/PRF/5 cells ( which have been established from a human primary hepatocellular carcinoma and proven to carry the hepatitis B virus DNA ) and inhibited proliferation of these cells in vitro
Hajnická et al., Acta Virol 1996 (Carcinoma, Hepatocellular) : We compared the ability of recombinant IFN-omega, IFN-alpha 2 and IFN-gamma to inhibit the production of viral hepatitis B surface antigen ( HBsAg ) in the human hepatoma cell line PLC/PRF/5